These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 24215209)

  • 21. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
    Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Yasuda Y; Saito K; Yuasa T; Uehara S; Kawamura N; Yokoyama M; Ishioka J; Matsuoka Y; Yamamoto S; Okuno T; Yonese J; Kihara K; Fujii Y
    Int J Clin Oncol; 2017 Dec; 22(6):1081-1086. PubMed ID: 28733795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
    Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R
    Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
    Fujita T; Iwamura M; Ishii D; Tabata K; Matsumoto K; Yoshida K; Baba S
    Int J Urol; 2012 Oct; 19(10):908-13. PubMed ID: 22671963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
    Izzedine H; Derosa L; Le Teuff G; Albiges L; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1128-1133. PubMed ID: 25795198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
    Lolli C; Basso U; Derosa L; Scarpi E; Sava T; Santoni M; Crabb SJ; Massari F; Aieta M; Conteduca V; Maruzzo M; La Russa F; Wheater M; Berardi R; Galli L; De Giorgi U
    Oncotarget; 2016 Aug; 7(34):54564-54571. PubMed ID: 27409344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
    van der Veldt AA; Eechoute K; Gelderblom H; Gietema J; Guchelaar HJ; van Erp NP; van den Eertwegh AJ; Haanen JB; Mathijssen RH; Wessels JA
    Clin Cancer Res; 2011 Feb; 17(3):620-9. PubMed ID: 21097692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
    Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
    Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
    Bozkurt O; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Karaca H; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
    Clin Genitourin Cancer; 2015 Dec; 13(6):548-54. PubMed ID: 26320661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
    Kubackova K; Melichar B; Bortlicek Z; Pavlik T; Poprach A; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Prausova J; Buchler T;
    Target Oncol; 2015 Dec; 10(4):557-63. PubMed ID: 25903462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma.
    Fukuda H; Kondo T; Iida S; Takagi T; Tanabe K
    Urol Oncol; 2016 Aug; 34(8):338.e1-9. PubMed ID: 27085488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
    Heng DY; Chi KN; Murray N; Jin T; Garcia JA; Bukowski RM; Rini BI; Kollmannsberger C
    Cancer; 2009 Feb; 115(4):776-83. PubMed ID: 19127560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.
    Haider MA; Vosough A; Khalvati F; Kiss A; Ganeshan B; Bjarnason GA
    Cancer Imaging; 2017 Jan; 17(1):4. PubMed ID: 28114978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
    Rebibo JD; Pfister C; Giwerc A; Defortescu G; Gouerant S; Di Fiore F; Nouhaud FX
    Prog Urol; 2016 Jan; 26(1):16-23. PubMed ID: 26455779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.